CN109722415A - 一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法 - Google Patents
一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法 Download PDFInfo
- Publication number
- CN109722415A CN109722415A CN201711116506.9A CN201711116506A CN109722415A CN 109722415 A CN109722415 A CN 109722415A CN 201711116506 A CN201711116506 A CN 201711116506A CN 109722415 A CN109722415 A CN 109722415A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- cell
- candidate stem
- progenitor cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (16)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711027708 | 2017-10-27 | ||
CN2017110277086 | 2017-10-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109722415A true CN109722415A (zh) | 2019-05-07 |
CN109722415B CN109722415B (zh) | 2021-01-26 |
Family
ID=66246216
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711116506.9A Active CN109722415B (zh) | 2017-10-27 | 2017-11-13 | 一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法 |
CN201711115779.1A Pending CN109722414A (zh) | 2017-10-27 | 2017-11-13 | 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基 |
CN201811256120.2A Active CN109735497B (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN201880069637.2A Active CN111278977B (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN202210384744.2A Pending CN115747165A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
CN202210385997.1A Pending CN114921415A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
CN201880069636.8A Active CN111278976B (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
CN202111463916.7A Pending CN114657140A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN202210443541.6A Pending CN114875026A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN201811256154.1A Withdrawn CN109735574A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
Family Applications After (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711115779.1A Pending CN109722414A (zh) | 2017-10-27 | 2017-11-13 | 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基 |
CN201811256120.2A Active CN109735497B (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN201880069637.2A Active CN111278977B (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN202210384744.2A Pending CN115747165A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
CN202210385997.1A Pending CN114921415A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
CN201880069636.8A Active CN111278976B (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
CN202111463916.7A Pending CN114657140A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN202210443541.6A Pending CN114875026A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达水平的方法 |
CN201811256154.1A Withdrawn CN109735574A (zh) | 2017-10-27 | 2018-10-26 | 一种提高胎儿血红蛋白表达的方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20200384032A1 (zh) |
EP (2) | EP3702459B1 (zh) |
JP (4) | JP2021502062A (zh) |
CN (10) | CN109722415B (zh) |
MA (2) | MA52665A (zh) |
PH (2) | PH12020550488A1 (zh) |
TW (2) | TW201930592A (zh) |
WO (2) | WO2019080920A1 (zh) |
ZA (2) | ZA202002203B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110511909A (zh) * | 2019-07-29 | 2019-11-29 | 吉林大学 | 体外扩增造血干细胞的生长因子组合物及其应用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018007987A (es) * | 2015-12-28 | 2019-01-10 | Novartis Ag | Composiciones y metodos para el tratamiento de hemoglobinopatias. |
CN109486814A (zh) * | 2017-10-31 | 2019-03-19 | 广东赤萌医疗科技有限公司 | 一种用于修复HBB1基因点突变的gRNA、基因编辑系统、表达载体和基因编辑试剂盒 |
CN112011576A (zh) * | 2019-05-31 | 2020-12-01 | 华东师范大学 | Crispr基因编辑技术在治疗地中海贫血中的应用 |
CN112391410B (zh) * | 2020-02-17 | 2024-04-02 | 华东师范大学 | 一种sgRNA及其在修复内含子异常剪接中的应用 |
WO2021037232A1 (zh) * | 2019-08-28 | 2021-03-04 | 甘李药业股份有限公司 | 编辑造血干/祖细胞中bcl11a基因的方法 |
WO2021037234A1 (zh) * | 2019-08-29 | 2021-03-04 | 广州辑因医疗科技有限公司 | 一种高效修复环状铁粒幼细胞性贫血基因突变的方法 |
CN112442516A (zh) * | 2019-08-29 | 2021-03-05 | 广州辑因医疗科技有限公司 | 一种高效修复环状铁粒幼细胞性贫血基因突变的方法 |
JP2022547105A (ja) * | 2019-09-04 | 2022-11-10 | 博雅▲輯▼因(北京)生物科技有限公司 | オフターゲット評価に基づく遺伝子編集治療の評価方法 |
WO2021049617A1 (ja) * | 2019-09-11 | 2021-03-18 | 国立大学法人 東京大学 | ヒト造血幹細胞を培養するために適したアルブミンフリーの無血清培地およびアルブミンフリーの培養方法 |
CN112746072A (zh) * | 2019-10-31 | 2021-05-04 | 广州瑞风生物科技有限公司 | 用于β-血红蛋白病基因编辑的sgRNA及应用 |
CN111876416B (zh) * | 2020-07-01 | 2021-09-03 | 广州瑞风生物科技有限公司 | 激活γ-珠蛋白基因表达的方法和组合物 |
CN114149990A (zh) * | 2020-09-08 | 2022-03-08 | 甘李药业股份有限公司 | 编辑造血干/祖细胞中bcl11a基因的方法 |
US11970713B2 (en) * | 2020-12-04 | 2024-04-30 | Ocgene Therapeutics Corporation | Method for long-term ex vivo maintenance or expansion of human erythroblast, human megakaryocyte-erythroid progenitor, or human common myeloid progenitor cell and application thereof |
CN113046330B (zh) * | 2021-03-23 | 2023-03-21 | 中吉智药(南京)生物技术有限公司 | 携带红系基因编辑系统的慢病毒及药物 |
IL306119A (en) * | 2021-04-02 | 2023-11-01 | Univ Shanghai Tech | Gene therapy for the treatment of beta-hemoglobinopathies |
CN114032240A (zh) * | 2021-11-02 | 2022-02-11 | 珠海横琴爱姆斯坦生物科技有限公司 | 一种用于提高基因敲除效率的方法 |
WO2023107675A2 (en) * | 2021-12-10 | 2023-06-15 | The Children's Medical Center Corporation | Combination bcl11a enhancer editing |
CN114317436A (zh) * | 2021-12-30 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | 一种重新激活人γ-珠蛋白基因表达的方法 |
CN116426472A (zh) * | 2023-06-08 | 2023-07-14 | 呈诺再生医学科技(北京)有限公司 | 一种促进造血干细胞或造血祖细胞分化为红细胞的诱导分化体系及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102643784A (zh) * | 2012-03-29 | 2012-08-22 | 中国人民解放军第四军医大学 | 一种造血干/祖细胞的体外扩增体系 |
CN105238758A (zh) * | 2015-09-17 | 2016-01-13 | 中国科学院广州生物医药与健康研究院 | 一种体外获得造血干/祖细胞的方法 |
WO2016176652A2 (en) * | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
CN107151655A (zh) * | 2017-04-10 | 2017-09-12 | 中国人民解放军第三O七医院 | 一种细胞扩增的方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100506978C (zh) * | 2001-09-21 | 2009-07-01 | 中国人民解放军军事医学科学院野战输血研究所 | 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化 |
CN101045914A (zh) * | 2006-03-29 | 2007-10-03 | 中国人民解放军军事医学科学院野战输血研究所 | 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用 |
CN102802412A (zh) * | 2009-12-08 | 2012-11-28 | 海玛奎斯特医药公司 | 用于治疗红细胞病症的方法及低剂量方案 |
JP6170080B2 (ja) * | 2012-02-24 | 2017-07-26 | フレッド ハッチンソン キャンサー リサーチ センター | 異常ヘモグロビン症の治療のための組成物および方法 |
EP4289948A3 (en) | 2012-05-25 | 2024-04-17 | The Regents of the University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
WO2014018423A2 (en) | 2012-07-25 | 2014-01-30 | The Broad Institute, Inc. | Inducible dna binding proteins and genome perturbation tools and applications thereof |
CN103667188B (zh) * | 2012-09-21 | 2016-02-24 | 北京市红十字血液中心 | 一种制备成熟红细胞的方法 |
JP6517143B2 (ja) | 2012-10-23 | 2019-05-22 | ツールゲン インコーポレイテッド | 標的dnaに特異的なガイドrnaおよびcasタンパク質コード核酸またはcasタンパク質を含む、標的dnaを切断するための組成物、ならびにその使用 |
US9822355B2 (en) * | 2012-11-27 | 2017-11-21 | Children's Medical Center Corporation | Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
PT3068881T (pt) * | 2013-11-13 | 2019-05-31 | Childrens Medical Center | Regulação da expressão de genes mediada por nucleases |
CA2938419A1 (en) * | 2014-01-30 | 2015-08-06 | Children's Hospital Medical Center | An improved fetal hemoglobin for genetic correction of sickle cell disease |
AU2015249381B2 (en) * | 2014-04-25 | 2020-04-30 | Children's Medical Center Corporation | Compositions and methods to treating hemoglobinopathies |
CN113699113A (zh) * | 2014-09-16 | 2021-11-26 | 桑格摩治疗股份有限公司 | 用于造血干细胞中核酸酶介导的基因组工程化和校正的方法和组合物 |
US11572543B2 (en) * | 2015-05-08 | 2023-02-07 | The Children's Medical Center. Corporation | Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction |
CN104877965B (zh) * | 2015-05-27 | 2018-04-20 | 上海厚东生物科技有限公司 | 一种制备成熟红细胞的方法 |
US9957501B2 (en) * | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
MX2018007987A (es) * | 2015-12-28 | 2019-01-10 | Novartis Ag | Composiciones y metodos para el tratamiento de hemoglobinopatias. |
CN105854017A (zh) * | 2016-03-01 | 2016-08-17 | 扬州大学 | 一种治疗β-地中海贫血的试剂及其应用 |
CN105754939A (zh) * | 2016-04-15 | 2016-07-13 | 广州市天河诺亚生物工程有限公司 | 一种提高脐带血红系祖细胞定向分化效果的方法 |
SG10202010261YA (en) * | 2016-04-18 | 2020-11-27 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
EP3596217A1 (en) * | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
-
2017
- 2017-11-13 CN CN201711116506.9A patent/CN109722415B/zh active Active
- 2017-11-13 CN CN201711115779.1A patent/CN109722414A/zh active Pending
-
2018
- 2018-10-26 CN CN201811256120.2A patent/CN109735497B/zh active Active
- 2018-10-26 CN CN201880069637.2A patent/CN111278977B/zh active Active
- 2018-10-26 WO PCT/CN2018/112068 patent/WO2019080920A1/zh active Application Filing
- 2018-10-26 CN CN202210384744.2A patent/CN115747165A/zh active Pending
- 2018-10-26 MA MA052665A patent/MA52665A/fr unknown
- 2018-10-26 CN CN202210385997.1A patent/CN114921415A/zh active Pending
- 2018-10-26 CN CN201880069636.8A patent/CN111278976B/zh active Active
- 2018-10-26 CN CN202111463916.7A patent/CN114657140A/zh active Pending
- 2018-10-26 WO PCT/CN2018/112027 patent/WO2019080917A1/zh active Application Filing
- 2018-10-26 EP EP18870546.1A patent/EP3702459B1/en active Active
- 2018-10-26 EP EP18870256.7A patent/EP3702458A4/en active Pending
- 2018-10-26 TW TW107138067A patent/TW201930592A/zh unknown
- 2018-10-26 CN CN202210443541.6A patent/CN114875026A/zh active Pending
- 2018-10-26 JP JP2020523720A patent/JP2021502062A/ja active Pending
- 2018-10-26 US US16/758,824 patent/US20200384032A1/en not_active Abandoned
- 2018-10-26 US US16/758,704 patent/US20200339979A1/en not_active Abandoned
- 2018-10-26 JP JP2020523710A patent/JP2021500058A/ja active Pending
- 2018-10-26 CN CN201811256154.1A patent/CN109735574A/zh not_active Withdrawn
- 2018-10-26 MA MA050844A patent/MA50844A/fr unknown
- 2018-10-26 TW TW107138062A patent/TW201922777A/zh unknown
-
2020
- 2020-04-24 PH PH12020550488A patent/PH12020550488A1/en unknown
- 2020-04-24 PH PH12020550487A patent/PH12020550487A1/en unknown
- 2020-05-04 ZA ZA2020/02203A patent/ZA202002203B/en unknown
- 2020-05-04 ZA ZA2020/02204A patent/ZA202002204B/en unknown
-
2022
- 2022-09-20 JP JP2022149586A patent/JP2022180510A/ja active Pending
- 2022-09-20 JP JP2022149587A patent/JP2022180511A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102643784A (zh) * | 2012-03-29 | 2012-08-22 | 中国人民解放军第四军医大学 | 一种造血干/祖细胞的体外扩增体系 |
WO2016176652A2 (en) * | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
CN105238758A (zh) * | 2015-09-17 | 2016-01-13 | 中国科学院广州生物医药与健康研究院 | 一种体外获得造血干/祖细胞的方法 |
CN107151655A (zh) * | 2017-04-10 | 2017-09-12 | 中国人民解放军第三O七医院 | 一种细胞扩增的方法 |
Non-Patent Citations (1)
Title |
---|
李猛等: "脐血来源造血干细胞体外培养扩增技术研究进展", 《中华细胞与干细胞杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110511909A (zh) * | 2019-07-29 | 2019-11-29 | 吉林大学 | 体外扩增造血干细胞的生长因子组合物及其应用 |
CN110511909B (zh) * | 2019-07-29 | 2022-01-04 | 吉林大学 | 体外扩增造血干细胞的生长因子组合物及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109722415A (zh) | 一种造血干细胞的培养组合物、培养基以及造血干细胞的培养方法 | |
CN103597072B (zh) | 单核细胞增殖剂、单核细胞增殖用培养基、单核细胞的制造方法、树突状细胞的制造方法、及树突状细胞疫苗的制造方法 | |
US8435785B2 (en) | Method of forming dendritic cells from embryonic stem cells | |
CN100478441C (zh) | 一种干细胞分离液及其用于干细胞分离的方法 | |
US20230106769A1 (en) | Serum-free medium and culturing method suited for culturing blood cells such as human hematopoietic stem cells | |
US20210054343A1 (en) | Endocardium-derived adult stem cells and method for producing same | |
CN109652369A (zh) | 利用外周血体外制备成熟红细胞的方法及制剂 | |
CN102643784A (zh) | 一种造血干/祖细胞的体外扩增体系 | |
CN106661551A (zh) | 由淋巴细胞产生多谱系潜能细胞的方法 | |
Jobin et al. | Heterogeneity of in vitro–cultured CD34+ cells isolated from peripheral blood | |
US20230027247A1 (en) | Small molecule compounds for amplifying hematopoietic stem cells, and combination thereof | |
CN109370988A (zh) | 干细胞体外扩增培养体系及其方法 | |
CN105062969B (zh) | 一种提高脐带血巨核祖细胞体外诱导分化效率的方法 | |
CN110055219A (zh) | 一种利用非动员外周血制备异质性造血干祖细胞的方法 | |
RU2628092C1 (ru) | Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+ | |
CN104622901B (zh) | 一种人胚胎干细胞定向分化为造血干细胞的方法 | |
US20230113074A1 (en) | Derivation of hepatocytes and hematopoietic progenitors from human embryonic stem cells | |
Fujikawa-Yamamoto et al. | Cell cycle, morphology and pluripotency of octaploid embryonic stem cells in comparison with those of tetraploid and diploid cells | |
KR101707387B1 (ko) | 적혈구의 인 비트로 대량 생산방법 및 이의 저장 방법 | |
Batista | A novel process for human hematopoietic stem cell selection | |
Ganassin | The development of in vitro techniques to facilitate the study of hemopoiesis in the rainbow trout, Oncorhynchus mykiss | |
Ko | Application of high-resolution division tracking to determine the role of regulators of haematopoietic cell development | |
WO2005033299A1 (en) | Method of repairing primate mammalian tissue | |
KR20100109542A (ko) | 생착능이 증가된 조혈줄기세포의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40005485 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220712 Address after: 102206 2nd floor, building 2, No.22, kekeyuan Road, Changping District, Beijing Patentee after: EDIGENE BIOTECHNOLOGY Inc. Address before: 100085 room A106, area a, 1 / F, No. 12, shangdixinxi Road, Haidian District, Beijing Patentee before: EDIGENE Inc. |